Gilead Sciences has entered into a definitive agreement to acquire Arcellx for an equity value of $7.8 billion. Arcellx is a biotechnology company focused on delivering a new class of immunotherapies for patients with cancer and other incurable diseases. The companies have an existing collaboration to co-develop and co-commercialise Arcellx’s lead pipeline candidate, anitocabtagene autoleucel […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!